Breast Lump Removal

About This Department

Of 3,305 people under forty seen at a one stop breast clinic over twenty months, 29 turned out to have cancer. That is 0.88 percent. Almost every lump examined in that clinic was something else, and most of those something elses did not need removing, which is why the useful question is not how the operation is done but whether the lump in front of you has to come out at all.

Free consultation

Ask whether it has to be removed before anybody books an operating room

A great many lumps are removed that could have been left alone, and a few are left alone that should have come out. Telling those apart takes three pieces of information and no more. Send the ultrasound report with the measurements and the assessment category, the mammogram report if you have had one, the needle biopsy result with its exact wording, a note of how long you have noticed the lump and whether it has changed, and your medication list. A breast surgeon and a radiologist review the file together and tell you whether removal is indicated, what watching instead would involve and how the two compare for you. No fee, no obligation, and a coordinator replies in your own language.

WhatsApp: +90 549 648 55 11 Send your biopsy report for review +90 549 648 55 11

What is actually in there

Five things account for nearly every lump anybody feels in a breast. They behave so differently that gathering them under one word does real damage, because the right answer for one is the wrong answer for the next. Knowing which of the five you have settles most of the argument.

Fibroadenoma

Solid, rubbery and mobile, made of ordinary breast tissue that has grown as a lump instead of as a sheet. It is the commonest solid lump in women under thirty. It is not a tumor in the sense that word usually carries, it does not turn into cancer, and it is the lump most often removed for no better reason than that it is there.

Cyst

Fluid held in a sac, most often appearing in the decade before menopause and often changing with the cycle, and although a cyst can be tender and can arrive over the course of a few days, it can also be emptied with a fine needle in a clinic room in about a minute. Surgery is very rarely the answer here.

Intraductal papilloma

Small and wart-like, sitting inside a milk duct usually close to the nipple, and the classic cause of a single duct discharging blood-stained fluid. It is benign. It sits in a gray zone, though, because the tissue around it occasionally hides something a needle missed, which is why the section further down gives it a heading of its own.

Phyllodes tumor

Rare, and it matters far out of proportion to how rare it is. A phyllodes tumor feels like a fibroadenoma, often looks like one on a scan, and can even be reported as one on a needle biopsy, yet it grows back locally if it is shelled out the way a fibroadenoma is. It needs a rim of normal tissue around it.

Cancer

Classically hard, fixed, irregular and painless, although a fair number break every one of those rules. This is the possibility the whole assessment is designed around, and the point of a modern breast clinic is to rule it in or out within days instead of weeks. In that one stop clinic, the median time from referral to diagnosis was thirteen days.

The odds it is cancer

Age changes this number more than anything else does, and by a great deal. A British study compared 3,994 women aged forty and over who developed breast cancer against 16,873 matched women who did not, then worked out what a symptom reported to a family doctor was actually worth as a warning. A lump was by far the strongest signal. Forty-four percent of the women who went on to be diagnosed had reported one in the preceding year, against 0.8 percent of the women who did not, and what that lump then predicted depended almost entirely on the age of the person carrying it. Other symptoms trailed well behind. Nipple retraction and nipple discharge both carried real weight in the same analysis, while breast pain on its own carried very little, which is worth holding on to if pain is what sent you looking in the first place and you have found nothing to feel.

A breast lump reported by a woman in her forties carried a 4.8 percent chance of cancer. The same lump reported by a woman over seventy carried a 48 percent chance. One symptom. A tenfold difference in what it ought to set in motion.

Below forty the figures fall away sharply again. Across those 3,305 young patients, cancer was found in 0.88 percent, and presenting with a lump instead of pain or another complaint raised the odds of a cancer diagnosis roughly elevenfold within that group, which sounds alarming until you notice what it is eleven times larger than. Read the two studies together and the practical message is short. A lump deserves proper assessment at any age, and how that assessment is likely to end differs at twenty-five, at forty-five and at seventy-five.

The three tests

Breast assessment worldwide rests on three legs, and their power comes from being read together.

Examination. A clinician feels the lump and records size, texture, mobility, skin changes and the state of the armpit, which is crude compared with the machines and still the leg that catches the thing the machines have not been pointed at.
Imaging. Ultrasound under about forty, ultrasound plus mammography over it. Ultrasound separates solid from fluid in seconds, which alone reclassifies a large share of lumps, and it then describes the shape and margins of a solid one well enough to grade its suspicion.
Needle sampling. A core biopsy takes a thin cylinder of the lump under local anesthetic and under ultrasound guidance and a pathologist reads the tissue, while fine needle aspiration, which collects cells and not tissue, is still used in some centers and answers a narrower question.

Combining them is what makes the approach trustworthy. In a series of 200 patients with a breast lump, the three tests taken together reached a sensitivity of 100 percent and a specificity of 99.3 percent, with a negative predictive value of 100 percent in that sample. Do not read a figure like that as a guarantee for every clinic on earth, because a single center reporting on two hundred patients cannot deliver one. Read it instead as evidence that agreement between three independent lines of evidence is a far stronger position than any of them alone, and the rule that follows is the rule that protects you. When all three point the same way, act on that. When one of the three disagrees with the other two, nobody should be reassured, and the lump should come out so a pathologist can look at the whole of it. A single test carrying the day is how mistakes get made, and the discipline of demanding all three before anybody commits to a plan is the least glamorous and most protective habit in this entire field.

What a benign result is worth

A needle biopsy reading benign is the piece of paper the whole plan rests on, so it is worth knowing how often that paper is wrong and what makes it wrong. One American hospital reviewed 952 consecutive core biopsies, then followed the benign ones either to surgery or for at least a year. Twenty-seven cancers had been missed. That works out at 9.1 percent, a much larger figure than most patients are ever given, and the detail underneath it is where the useful part lives.

For lumps you can feel, a core biopsy guided by ultrasound missed cancer 3.6 percent of the time. The same biopsy taken by feel alone, with no imaging watching the needle go in, missed it 13.3 percent of the time. Whether somebody was looking at a screen changed the error rate almost fourfold.

Two things follow. Ask whether your biopsy was image guided, and if it was not, treat the result with more caution than the word benign invites. Ask also whether the result was formally compared against the scan, since a benign report on a lump that looked suspicious is no reassurance at all but a disagreement, and disagreement is the trigger for removal. Where the scan and the needle do agree, the comfort is real. Among 312 lumps that could be felt but looked probably benign on ultrasound, 310 were benign and two were cancer, giving a false negative rate of 0.6 percent and a negative predictive value of 99.4 percent. That was the study's argument for offering short interval scanning in place of immediate biopsy in that specific group. It is also a fair account of how much weight concordant results will bear. Neither question takes more than a few seconds to ask, and between them they settle whether the paper in your hand is a real answer or merely the absence of one, which is a distinction the word benign is very good at hiding.

A fibroadenoma left alone

Very few patients are ever shown what happens to a fibroadenoma that is simply watched, and the numbers are more interesting than the operation. Edinburgh surgeons diagnosed 219 fibroadenomas in 202 women, offered removal to everybody, and then followed the 163 lumps whose owners declined for a minimum of two years. Forty-two of those lumps, 26 percent, disappeared completely. Nineteen more got measurably smaller. Eighty-nine sat there unchanged for the whole follow-up, which is 55 percent, and for a woman who has been told what the lump is that turns out to be surprisingly easy to live with. Only thirteen grew. All thirteen were removed on that basis and all thirteen proved to be fibroadenomas under the microscope, so growth here was never a sign of anything sinister, only a reason to stop watching. Worth sitting with that last figure for a moment, because it is the one most often used as an argument for operating early. Growth in a lump that three tests have already agreed is a fibroadenoma turned out, in every single case in this series, to mean nothing more than that the fibroadenoma had grown. Add the first three groups and 93 percent of these lumps never needed an operation. The price of finding that out was patience, and the authors concluded that conservative management under the age of forty was safe and acceptable to most women.

There is one caveat about the future that patients are often given too flatly. Vanderbilt researchers traced 1,835 women who had a fibroadenoma removed between 1950 and 1968, counted the breast cancers appearing over the following decades, and found the group running at 2.17 times the expected rate with a confidence interval from 1.5 to 3.2, a headline that hides the part worth knowing. The excess sat almost entirely in two subgroups. A complex fibroadenoma, meaning one containing cysts, calcification or certain other features the pathologist looks for, carried a relative risk of 3.10. Proliferative change in the ordinary breast tissue sitting next to the lump carried 3.88. Two-thirds had a plain fibroadenoma and no family history. In that two-thirds the risk was not raised at all, so the honest sentence is that a fibroadenoma is not itself a risk factor and that removing one occasionally uncovers a risk factor lying beside it. If your lump has already been taken out, check whether the report uses the word complex and what it says about the surrounding tissue. Those two lines change how often anybody should be looking at your breasts for the next twenty years, and they change nothing at all about the lump that has gone.

How watching actually works

Watching a lump is a plan with rules, and a patient told to keep an eye on it and come back if worried has not been given one. A real surveillance plan has five parts.

The diagnosis is settled before the watching starts. All three tests done, all three agreeing, and the agreement written down somewhere you can see it. Watching a lump nobody has properly characterized is not surveillance. It is delay wearing surveillance as a costume.

The lump is measured in millimeters and the number is recorded. Two dimensions at least, from the ultrasound report and not from anybody's fingers. Everything that happens afterwards is a comparison against this number, so a baseline described only as a small lump in the upper outer quadrant is useless.

The next scan has a date on it. Six months is the usual first interval, then twelve, and most units stop after two or three stable scans in a young patient with a classic fibroadenoma. Book it before you leave, because a plan that depends on you remembering in half a year is the plan that fails.

Somebody has decided in advance what counts as a change. A Korean group looking at lesions first called probably benign found that a growth of 39 percent of the starting diameter picked up cancer with 95 percent sensitivity, though at a specificity of only 53.5 percent, which means the threshold catches nearly everything and also sends plenty of harmless lumps for a needle. Your unit will use its own figure. Ask what it is.

One named person owns the plan. Surveillance across borders falls apart when nobody at home knows it is running. Leave with the baseline measurements, the interval, the threshold and a letter addressed to a breast specialist near you, and the plan survives the flight.

When it does come out

Set against all that, these are the situations where removal earns its place and does not merely fill a gap in the conversation.

Your three tests disagree. Far and away the most important entry on this list. A benign needle result on a lump that looked suspicious, or a suspicious feel with a bland scan, means the tissue has to be seen in full and not sampled.
Your biopsy shows something other than a plain fibroadenoma. Papilloma, phyllodes, atypia and a handful of other reports each carry their own rule, and those rules get a section of their own further down.
It is growing. A lump enlarging on repeat measurement stops being a candidate for watching, whatever the first biopsy said.
It is big enough to change the shape of the breast. Size alone is a legitimate reason. A lump distorting the contour, or pressing enough to be uncomfortable, is a problem in its own right and needs no pathological excuse.
It hurts, or it catches. Persistent local pain traceable to the lump itself, as opposed to the general cyclical soreness of breast tissue, is a fair reason to remove it.
You cannot live alongside it. A real reason, and one worth saying out loud. Among 255 women attending a clinic with benign breast disease, 52 percent screened positive for distress, with anxiety reported by 43.5 percent and fear by 21.2 percent. Somebody who checks a benign lump every morning and sleeps badly because of it is not being irrational, and removal treats that.

Cysts

Cysts get their own section because the treatment has almost nothing in common with everything above. Nothing is cut. What matters is the word the ultrasound uses, and there are broadly two answers.

A simple cyst

Thin walled, filled with clear fluid, black on the scan with nothing inside it. A simple cyst on ultrasound is benign and needs no treatment whatsoever unless it is uncomfortable, in which case a fine needle empties it in a clinic room and the lump vanishes as you watch. A cyst that refills, and a minority do, can simply be drained again, and cutting one out is almost never the right operation, which makes a recommendation to do so worth a second opinion.

A complicated or clustered cyst

Debris inside the fluid, a thick wall, a solid area or several small cysts packed together, and the reassurance weakens. A Korean review tracked lesions first called probably benign and then seen to change on repeat scanning, and among those 289 changed lesions the overall cancer rate was 6.9 percent. Broken down by what each lesion had originally looked like, complicated cysts ran at 5 percent and clustered cysts at 33.3 percent, the highest figure in the study. Just over half the cancers found were the pre-invasive kind. The lesson is narrow and specific. A cyst that is not simple, or a cyst that has changed since the last scan, is not in the reassuring category, and clustered cysts in particular deserve a needle and not another six months of watching. A cyst aspirated once and refilling within weeks deserves the same attention, because a lump that comes straight back has not been explained by the aspiration, and fluid that comes out bloodstained should always be sent for examination.

The day itself

An open excision of a benign lump takes about half an hour of surgery. This is what fills the day around it.

Somebody finds the lump again that morning. An ultrasound probe locates it and the skin is marked while you sit up, because a lump that is easy to feel standing can become impossible to find lying flat under an anesthetic. If it cannot be felt at all, a fine wire or a small marker is placed under scan guidance to lead the surgeon to it.
An incision is planned around the scar. Cuts follow the natural curves of the breast, and where the anatomy allows, the incision is hidden at the edge of the areola or in the fold underneath instead of sitting directly over the lump. Say beforehand if the scar matters to you, because this is decided in that conversation and not in the operating room.
Everything comes out in one piece. A benign lump is shelled out of the tissue around it with as little normal breast removed as possible. Where the diagnosis is uncertain, or where phyllodes is on the list, a rim of normal tissue goes with it, and that difference is settled before you go to sleep.
Closing the cavity is what stops a dent forming. Breast tissue is mobilized and stitched across the space left behind. Skipping this step is the commonest cause of a visible hollow months later, and it costs a few minutes.
Skin is closed under the surface. Dissolving stitches beneath the skin, glue or fine tape on top, nothing to be pulled out later. Most patients go home the same day.
Tissue goes to pathology. Whatever the needle said, the removed tissue is examined in full and that report is the final word on what the lump was, arriving in something like a week, and you should have it in writing before you fly home.

General anesthesia is usual for an open excision. A small superficial lump can be done under local anesthetic with sedation instead, and that is worth asking about if a general anesthetic is what frightens you.

Needle against knife

Open surgery is no longer the only way to get a benign lump out. Vacuum assisted excision uses a wide bore probe passed through a single small skin puncture under ultrasound control, and the lump is removed in strips through the probe under local anesthetic while you lie on a couch. It leaves a mark a few millimeters long and no scar to speak of. It is not equivalent to surgery in every respect, and the table sets out where the two diverge.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Vacuum assisted excision compared with open surgical removal of a benign lump
Point of difference	Vacuum assisted excision	Open excision
Anesthetic	Local, awake, on an outpatient couch.	Usually general, occasionally local with sedation.
What it leaves	A puncture mark of a few millimeters. Mean satisfaction with appearance was scored at 4.03 out of 5 in one series.	A true scar, its length set by the lump, positioned to hide it where the anatomy allows.
Complete removal	98.8 percent across 163 fibroadenomas up to four centimeters, falling with size to 91.0 percent for 89 lesions larger than three.	The lump is taken out in one piece under direct vision, so completeness is not usually in question.
Coming back	No recurrences in one series of 113 patients. A smaller series of 38 recorded 13.16 percent at one year, so the published range is wide.	Uncommon for a fibroadenoma taken out whole. A new lump elsewhere in the breast is a separate event.
Bleeding into the breast	3.06 percent for lumps up to four centimeters, rising to 19.1 percent once the lump is larger than three.	Bleeding points are seen and controlled before closure, which is the main advantage of an open field.
Where it should not be used	Suspected phyllodes, papillomas over three centimeters, very vascular lesions and any lump whose diagnosis is unsettled.	Preferred whenever a clear margin of normal tissue around the lump is part of the point of operating in the first place.
Time on the day	Twenty to forty minutes. You walk out afterwards.	Half an hour of surgery, with admission, anesthesia and a recovery period either side of it, so the day is largely gone.

Fibroadenomas have a third option worth knowing about, though far fewer units offer it. Cryoablation freezes the lump through a needle and leaves the body to reabsorb it. In 78 women treated with a liquid nitrogen system, the lumps had shrunk by a median of 80.6 percent at six months and 92.9 percent at twelve, with a single minor complication across 123 treated lesions. Note what it does not give you. No tissue comes out. Nobody ever confirms under a microscope what was frozen, so the diagnosis has to be beyond doubt before anybody starts.

What can go wrong

Removing a benign breast lump sits among the safer operations in general surgery and the honest list is short, so read it against the fact that most of these lumps did not have to be removed, because that is what makes even small risks worth weighing.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

What happens after removal of a benign breast lump, and how each problem is handled
Problem	How it shows	What is done
Bleeding into the wound	Swelling, firmness and bruising in the first day or two.	Small collections settle on their own over weeks. A large or tense one is drained, occasionally back in the operating room.
Fluid collecting in the space	A soft swelling appearing after a week or so where the lump used to be.	Usually left alone and reabsorbed. Drained with a needle if it is uncomfortable or the skin is under tension.
Infection	Spreading redness, increasing pain after day three, fever or discharge.	Antibiotics, and drainage if an abscess has formed. Uncommon in clean breast surgery.
A dent or asymmetry	A visible hollow over the scar, usually clear by two or three months.	Largely prevented by closing the cavity at the time. Correction afterwards is possible but is a second operation.
Numbness near the scar	A patch of altered feeling in the skin, sometimes including the nipple after a cut at the areolar edge.	Usually improves over months. A small area can stay permanently numb.
A scar that thickens	Raised, red or itchy months later, and more likely in younger patients and darker skin.	Silicone sheeting, massage and time. Say beforehand if you have thickened a scar in the past.
The pathology surprises everyone	The full specimen shows something the needle did not, most often a phyllodes tumor read as a fibroadenoma.	Discussed at a multidisciplinary meeting, and a second operation for a wider margin is sometimes advised.

None of this argues against the operation when there is a reason for it. It argues for knowing what the reason is.

Papilloma and phyllodes

Two biopsy results turn the general argument of this page on its head, and if either appears on your report the watch and wait discussion is over.

Papilloma, where the literature openly disagrees

A meta-analysis of 13 studies found that papillomas without atypia, where the biopsy and the scan agreed with each other, were upgraded to cancer at surgery only 1.4 percent of the time, with a confidence interval of 0.8 to 2.0 percent. Its authors concluded that such lesions can safely be watched. A multicenter series of 1,343 patients found 9.4 percent instead. The gap is real, it probably comes down to how strictly agreement between scan and biopsy was checked in each set of studies, and you should know it exists rather than be handed whichever figure suits the plan.

Papilloma with atypia is a different lesion entirely

In that same multicenter series, papillomas reported with atypia were upgraded to cancer in 44.7 percent of cases, 55 out of 123. Nobody watches that. One word on your report moves the answer from a conversation to a recommendation, so check whether it appears.

Phyllodes, and why the needle cannot be trusted here

In 129 patients with a proven phyllodes tumor, the grade on the core biopsy matched the grade on the removed specimen only about 60 percent of the time, and every mismatch went the same way. The needle underestimated the tumor. Larger tumors were more often wrong. This is why a phyllodes tumor is never shelled out the way a fibroadenoma is.

What phyllodes does if the margin is thin

Pooling 52 studies gave local recurrence rates of 7.1 percent for benign phyllodes, 16.7 percent for borderline and 25.1 percent for malignant. Both a one millimeter and a one centimeter margin were associated with significantly lower recurrence, and the reviewers argued for at least a centimeter. That view is contested, and a more recent synthesis holds that no ideal margin can be pinned down from the evidence available. What nobody disputes is that a margin is needed, and the practical consequence for you is that a phyllodes tumor should be operated on by somebody who knew it was phyllodes before the operation started rather than discovered it afterwards, because the second situation frequently means going back for a wider excision that a single correctly planned operation would have avoided.

Recovery and flying home

The first two days

Soreness more than pain, controlled by simple painkillers, and a supportive bra worn day and night to stop the breast moving. Bruising appears and spreads downwards. You can shower once you are told the dressing allows it, usually within a day or two.

The first week

Desk work is reasonable after two or three days. Lifting, pushing and anything pulling across the chest waits. The wound is checked once before you travel, and this is when the pathology result should be arriving.

Flying

Generally cleared at around five to seven days after an open excision, once the wound is dry and settled. After vacuum assisted excision, most patients fly the next day. Ask for the clearance in writing if your airline or insurer wants it.

Weeks two to six

Full activity comes back gradually and exercise involving the chest returns at around three to four weeks. The scar goes through a red, firm phase before it fades, and it keeps improving for a year or more.

Follow-up after returning home

One wound check with a doctor or nurse near you in the first fortnight, and one appointment with a breast specialist once the pathology report is in your hands. If the report mentions complex, atypia, phyllodes or proliferative change, that appointment sets your imaging schedule for years and should not be skipped. Get in touch with the hospital about redness spreading outwards from the wound, pain increasing after the third day, a fever, discharge, or a breast swelling rapidly and becoming tense. The last of those needs to be seen the same day.

Questions to ask

Six things to establish, and the answers will tell you more than any second opinion on the images. Start with whether your examination, your scan and your biopsy agree with one another, because that is the question the whole assessment exists to answer and it should get a straight yes or no. Then ask whether the biopsy was taken under ultrasound guidance, since the miss rate for a palpable lump was 3.6 percent with imaging and 13.3 percent without it. Ask next for the pathology report word for word. Fibroadenoma, complex fibroadenoma, papilloma, papilloma with atypia and phyllodes lead to five different plans, and the summary you were given out loud may well have flattened the distinction between them. Ask what happens if you do nothing for six months, because a surgeon who can describe the watching option in detail is a surgeon who has genuinely considered it. Ask whether vacuum assisted excision would suit your lump, and if the answer is no, listen for whether the reason is about your particular lump or about what the unit happens to offer. Finish with the scar. Where it will sit and whether the cavity will be closed are both decided before the operation, and both are far harder to fix afterwards than to plan beforehand.

Reading a quote

No figure appears on this page, and a number quoted before the diagnosis is settled is a number for somebody else. Five things belong in writing before you compare two offers. Whether the assessment sits inside the price, since a patient arriving with a scan and no biopsy cannot be operated on until that has been done, and this is a common gap between what was quoted and what is needed. Whether the quote assumes open surgery or vacuum assisted excision, because they are different procedures at different prices and the wording does not always make clear which one you have been offered. Whether the pathology examination of the removed lump is included, which is the entire point of the exercise and should never be an extra. How many nights are budgeted, given that most of these patients go home the same day and a quote assuming several is quoting for something else, and what happens to the price if the pathology comes back showing phyllodes or atypia and a second, wider operation is advised.

Your own file moves the total less here than in most operations. Lump size, whether the lump can be felt at all and so whether wire localization is needed, and whether more than one lump is being removed at the same sitting are the three variables that actually shift it.

Packages published by Turkish hospitals and medical travel agencies for benign breast surgery generally include the airport transfer, pre-operative testing, the surgeon and anesthesia fees, the operating room, the pathology, an interpreter and the review before departure. They generally exclude flights, insurance, treatment of a complication, a second operation prompted by the pathology, extra nights and hotel stays past an agreed number. Read what arrives against both lists.

Coming to Istanbul

Seven to ten days covers an open excision comfortably, and a patient arriving with the assessment already complete can often do it in five. Vacuum assisted excision needs far less. Assessment takes the first day or two, the procedure fills part of a morning, and the pathology report decides how long you stay after that, since carrying it home in your hand is worth waiting for. Send the biopsy report before anything else, with its wording intact. A scan without a tissue diagnosis cannot be turned into a plan for surgery, and neither can a report saying only that a lump was seen. Add the ultrasound report with the measurements and the assessment category, the mammogram report if you are over forty, any previous imaging so change over time can be judged, and a note of how long the lump has been there.

Say in your first message how you feel about a scar and how you feel about waiting, because those two answers shape the recommendation more than anything in the imaging does. Somebody who would prefer not to be operated on at all needs a different consultation from somebody who wants the lump gone this month, and both are reasonable positions. Only one coordinator holds your file from the first message to discharge, and the international patients team works in English, Arabic, French, Russian, Serbian, Romanian and Spanish, with other languages arranged on request. Ask in your first message if you would prefer a female physician. Someone can stay overnight with you on the ward, where the rooms carry a companion bed. Meals from the hospital kitchen cover halal, vegetarian and diabetic diets and a prayer room is available. The international patients office books accommodation for both of you, arranges the airport transfer and daily transport, and prepares the appointment confirmation and the invitation letter naming the hospital and your treating doctor for a medical visa application, around ten days before travel.

Take home the pathology report itself and not a summary of it. It should name the lesion in full, say whether the word complex was used, describe the surrounding breast tissue, and state whether the lesion reached the edge of the specimen. Add the operation note, the wound care instructions and the date when the scar should next be looked at. Address the file to a breast specialist at home and book that appointment before you fly, because a report mentioning atypia, phyllodes or proliferative change changes what your follow-up should look like for years, and somebody near you has to hold that thread. Once you are back home, your coordinator stays reachable on the same WhatsApp number, so a question about the wound or a line in the report reaches somebody with your notes in front of them. Send that first message before you have decided anything, because the value of the review is in learning what your options actually are, and a file that arrives complete comes back with a straight answer instead of a request for the missing scan.

Breast lump removal FAQ

How likely is a new breast lump to be cancer?

Mostly a matter of age. Among 3,305 patients under forty seen at a one stop clinic, 0.88 percent had cancer. In primary care, a lump reported by a woman in her forties carried a 4.8 percent chance, rising to 48 percent above seventy. Get it assessed at any age, and calibrate your alarm to your own decade.

Does a fibroadenoma have to be removed?

Usually not, once the three tests agree. Of 163 fibroadenomas watched for at least two years, 26 percent vanished completely, 12 percent shrank and 55 percent stayed the same. Only 8 percent grew, and all of those proved to be fibroadenomas when they came out.

Can a fibroadenoma turn into cancer?

No. Followed over decades, women with a fibroadenoma had 2.17 times the expected rate of later breast cancer, but that excess sat in those with a complex fibroadenoma or proliferative change in the tissue beside it. Two-thirds of the women had neither, and no raised risk at all.

Can it be done without a scar?

Vacuum assisted excision goes in through a puncture and removed the lump completely in 98.8 percent of 163 fibroadenomas up to four centimeters. Above three centimeters, completeness fell to 91.0 percent and bleeding into the breast rose to 19.1 percent, so size decides whether it suits you.

How reliable is a benign needle biopsy?

Reliable when the needle was guided by ultrasound and the result matches the scan. In one review of 952 core biopsies the overall miss rate was 9.1 percent, but for lumps that could be felt it was 3.6 percent with imaging guidance against 13.3 percent without it. Ask which yours was.

My report says intraductal papilloma. Does it have to come out?

It depends on one word. Without atypia and with the scan agreeing, a meta-analysis of 13 studies found cancer at surgery in 1.4 percent and its authors supported watching, though a large multicenter series reported 9.4 percent. With atypia, 44.7 percent were upgraded to cancer, and removal is advised.

What is a phyllodes tumor and why is it treated differently?

A rare lump that imitates a fibroadenoma and comes back if it is simply shelled out. Core biopsy matched the final grade only about 60 percent of the time in 129 patients, always underestimating it. Local recurrence across 52 studies ran at 7.1 percent for benign, 16.7 percent for borderline and 25.1 percent for malignant tumors.

Will removal affect breastfeeding?

Rarely, after a single benign excision. The risk relates to how many ducts are divided, which is why an incision at the edge of the areola is chosen with more thought in younger patients. Say before surgery that you plan to breastfeed and the approach can be planned around it.

How long should I stay in Turkey?

Seven to ten days for an open excision, and five is achievable if the assessment is already done. Flying is generally cleared at five to seven days once the wound is dry. Vacuum assisted excision usually allows travel the following day.

References

Walker S, Hyde C, Hamilton W. Risk of breast cancer in symptomatic women in primary care, a case-control study using electronic records. British Journal of General Practice. 2014;64(629):e788-793.
Mazari FAK, Sharma N, Reid D, Horgan K. The need for triple assessment and predictors for diagnosis of breast cancer in patients under 40 years of age. Clinical Radiology. 2018;73(8):758.e19-758.e25.
Jan M, Mattoo JA, Salroo NA, Ahangar S. Triple assessment in the diagnosis of breast cancer in Kashmir. The Indian Journal of Surgery. 2010;72(2):97-103.
Shah VI, Raju U, Chitale D, Deshpande V, Gregory N, Strand V. False-negative core needle biopsies of the breast, an analysis of clinical, radiologic, and pathologic findings in 27 consecutive cases of missed breast cancer. Cancer. 2003;97(8):1824-1831.
Park YM, Kim EK, Lee JH, Ryu JH, Han SS, Choi SJ, Lee SJ, Yoon HK. Palpable breast masses with probably benign morphology at sonography, can biopsy be deferred? Acta Radiologica. 2008;49(10):1104-1111.
Dixon JM, Dobie V, Lamb J, Walsh JS, Chetty U. Assessment of the acceptability of conservative management of fibroadenoma of the breast. British Journal of Surgery. 1996;83(2):264-265.
Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD, Rados MS, Schuyler PA. Long-term risk of breast cancer in women with fibroadenoma. The New England Journal of Medicine. 1994;331(1):10-15.
Jang JY, Kim SM, Kim JH, Jang M, La Yun B, Lee JY, Lee SH, Kim B. Clinical significance of interval changes in breast lesions initially categorized as probably benign on breast ultrasound. Medicine. 2017;96(12):e6415.
Rupa R, Kushvaha S. Vacuum-assisted excision, scarless solution for fibroadenoma breast, a single-center experience. The Indian Journal of Radiology and Imaging. 2021;31(4):844-849.
Wang B, Jiang Y, Zhang MK, Li SY, Niu RL, Liu G, Wang ZL. Efficacy and safety of percutaneous ultrasound-guided vacuum-assisted excision for the treatment of clinical benign breast lesions larger than 3 cm, a retrospective cohort study. Annals of Translational Medicine. 2022;10(24):1345.
Terro K, ALhajri K, ALshammari M. Outcomes of vacuum-assisted breast biopsy for management of benign breast masses. The Gulf Journal of Oncology. 2023;1(43):25-32.
Filipov T, Teutsch B, Vass D, Budinszki B, Hegyi P, Doros A, Forrai G, Deak PA. Cryoablation for fibroadenoma with liquid nitrogen based system, a retrospective analysis of prospectively collected data. PLoS One. 2026;21(1):e0340969.
Keating N, Cevik J, Hopkins D, Lippey J. Malignant upgrade rate and associated clinicopathologic predictors for concordant intraductal papilloma without atypia, a systematic review and meta-analysis. Journal of Surgical Oncology. 2024;129(6):1025-1033.
Oktay A, Aslan O, Taskin F, et al. Outcomes of high-risk breast lesions diagnosed using image-guided core needle biopsy, results from a multicenter retrospective study. Diagnostic and Interventional Radiology. 2023;29(4):579-587.
Yu CY, Huang TW, Tam KW. Management of phyllodes tumor, a systematic review and meta-analysis of real-world evidence. International Journal of Surgery. 2022;107:106969.
Choi J, Koo JS. Comparative study of histological features between core needle biopsy and surgical excision in phyllodes tumor. Pathology International. 2011;62(2):120-126.
Gao Y, Wang J, Guo J, Gao J. Psychological distress in Chinese women with benign breast disease and breast cancer during diagnosis, a cross-sectional study. Advances in Clinical and Experimental Medicine. 2026;35(2):231-241.